Émélie Braschi, Samantha S. Moe
Abstract
Open-access reader
What are the risks and benefits of using topical calcineurin inhibitors for atopic dermatitis? For improvement of atopic dermatitis, 0.1% tacrolimus ointment is at least equivalent to moderate-potency topical corticosteroids. Use of 1% pimecrolimus cream is better than placebo but is likely
OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
What are the risks and benefits of using topical calcineurin inhibitors for atopic dermatitis? For improvement of atopic dermatitis, 0.1% tacrolimus ointment is at least equivalent to moderate-potency topical corticosteroids. Use of 1% pimecrolimus cream is better than placebo but is likely
Key concepts: Pimecrolimus, Atopic dermatitis, Calcineurin, Tacrolimus, Medicine, Dermatology, Placebo, Potency